logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

LINGBAO GOLD (03330) will distribute a final dividend of HK$0.057237 per share on June 23rd.

date
21:07 19/05/2026
avatar
GMT Eight
Lingbao Gold (03330) announced that it will distribute a dividend of HKD 0.057237 per share for the fiscal year ending December 31, 2025, which will be paid on June 23, 2026.
LINGBAO GOLD (03330) announces that it will distribute a dividend of HK$0.057237 per share for the fiscal year ending December 31, 2025, to be paid on June 23, 2026.
Related Articles
HK Stock
DUALITYBIO-B (09606) plans to repurchase up to $40 million worth of shares, and founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.
HK Stock
XD INC (02400) repurchased 3.136 million shares cancelled on May 19th.
HK Stock
IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
DUALITYBIO-B (09606) plans to repurchase up to $40 million worth of shares, and founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.
HK Stock
XD INC (02400) repurchased 3.136 million shares cancelled on May 19th.
HK Stock
IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
HK Stock
RECOMMEND
Hong Kong Tech Stocks Struggle but Institutions See Long‑Term Value
Hong Kong Tech Stocks Struggle but Institutions See Long‑Term Value
icon
19/05/2026
Hong Kong Indices Fall as Tech and Auto Stocks Slide, Li Auto Plunges
Hong Kong Indices Fall as Tech and Auto Stocks Slide, Li Auto Plunges
icon
19/05/2026
HKEX Confident in Handling Over 400 IPO Applications
HKEX Confident in Handling Over 400 IPO Applications
icon
19/05/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.